CORVUS PHARMAC. DL-,0001

At the Cantor Fitzgerald Healthcare Conference, Corvus Pharmaceuticals presented an expanded development plan for the oral ITK inhibitor Soquelitinib, which will be tested in indications such as peripheral T‑cell lymphoma (Phase III), moderate to severe atopic dermatitis (Phase II), asthma and hidradenitis suppurativa. According to the company, Phase II data in atopic dermatitis showed a safety profile similar to placebo and efficacies that, depending on the endpoint, could be comparable to JAK inhibitors or biologics; biomarkers suggest an immune rebalancing effect. After a capital raise, Corvus has about $214 million in cash, which is expected to fund operations through mid‑2028; key catalysts include data from China in December 2024, a futility analysis for PTCL in Q1 2025 and Phase II topline data for dermatitis in Q3 2025, while investment risk remains dependent on outstanding study results and competitive pressure. » More on de.investing.com

Corvus published in Blood the phase‑1/1b results for Soquelitinib in T‑cell lymphomas. In the 200 mg twice‑daily cohort, six complete and three partial responses were observed among 36 patients; in patients with 1–3 prior therapies, nine of 24 achieved an objective response, with median PFS of 6.2 months and median OS of 28.1 months. The agent was well tolerated up to 600 mg twice daily, showed no dose‑limiting toxicities, and via selective ITK inhibition leads to Th1 skewing; Corvus plans a phase‑3 trial in relapsed/refractory PTCL and is conducting further phase‑2 studies in atopic dermatitis and other indications. » More on de.investing.com

Corvus Pharmaceuticals reported strong Phase 1 data for oral ITK inhibitor soquelitinib in atopic dermatitis with 75% EASI-75 at the highest dose versus 20% for placebo and sustained benefit after dosing stopped. The company is advancing a ~200-patient Phase 2 SEERA-1 trial with enrollment due to complete in early 2027 and results expected the following quarter, while also funding a China partner trial. Corvus ended the quarter with $215 million in cash after a $189 million raise, but R&D costs and net losses rose sharply as the company remains essentially a one-drug story. A Phase 3 lymphoma program faces a futility review in Q1 2027 and short interest remains elevated at about 24.7%, highlighting execution and clinical risk ahead. » More on finance.yahoo.com